[P02BB01, trichlorfon, Metrifonate may increase the bradycardic activities of Oxprenolol.]
[S02DA03, antipyrine, Antipyrine may decrease the antihypertensive activities of Oxprenolol.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Oxprenolol.]
[L04AA27, fingolimod, Oxprenolol may increase the bradycardic activities of Fingolimod.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Oxprenolol.]
[J01EC02, sulfadiazine, The therapeutic efficacy of Sulfadiazine can be increased when used in combination with Oxprenolol.]
[J01EC01, sulfamethoxazole, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Oxprenolol.]
[S01AB02, sulfisoxazole, The therapeutic efficacy of Sulfisoxazole can be increased when used in combination with Oxprenolol.]
[M01AB02, sulindac, Sulindac may decrease the antihypertensive activities of Oxprenolol.]
[N05AL01, sulpiride, Sulpiride may increase the bradycardic activities of Oxprenolol.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Sulthiame.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be increased when used in combination with Oxprenolol.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be increased when used in combination with Oxprenolol.]
[M01AX04, apazone, Azapropazone may decrease the antihypertensive activities of Oxprenolol.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Mercaptopurine.]
[N06DA01, tacrine, Tacrine may increase the bradycardic activities of Oxprenolol.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Oxprenolol.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Oxprenolol.]
[R03CC03, terbutaline, Oxprenolol may decrease the bronchodilatory activities of Terbutaline.]
[N07XX06, tetrabenazine, The metabolism of Tetrabenazine can be decreased when combined with Oxprenolol.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Tetracaine.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Oxprenolol.]
[L04AX02, thalidomide, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Theobromine.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Oxprenolol.]
[R06AD03, thiethylperazine, The serum concentration of Oxprenolol can be increased when it is combined with Thiethylperazine.]
[L01AC01, thiotepa, Thiotepa may increase the bradycardic activities of Oxprenolol.]
[N05CA19, thiopental, Thiopental may increase the hypotensive activities of Oxprenolol.]
[N05AB08, thioproperazine, The serum concentration of Oxprenolol can be increased when it is combined with Thioproperazine.]
[N05AC02, thioridazine, The metabolism of Oxprenolol can be decreased when combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Thiothixene.]
[C01BB04, aprindine, Aprindine may increase the arrhythmogenic activities of Oxprenolol.]
[B02AB01, aprotinin, Aprotinin may increase the bradycardic activities of Oxprenolol.]
[G04BE06, moxisylyte, Moxisylyte may decrease the antihypertensive activities of Oxprenolol.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Tiapride.]
[B01AC05, ticlopidine, The metabolism of Oxprenolol can be decreased when combined with Ticlopidine.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Tilidine.]
[S01ED01, timolol, The risk or severity of adverse effects can be increased when Timolol is combined with Oxprenolol.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be increased when used in combination with Oxprenolol.]
[M02AX02, tolazoline, Oxprenolol may increase the orthostatic hypotensive activities of Tolazoline.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be increased when used in combination with Oxprenolol.]
[M02AA21, tolmetin, Tolmetin may decrease the antihypertensive activities of Oxprenolol.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Tolperisone.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Oxprenolol.]
[N06AF04, tranylcypromine, The metabolism of Oxprenolol can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Oxprenolol.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Oxprenolol.]
[C03DB02, triamterene, The risk or severity of adverse effects can be increased when Triamterene is combined with Oxprenolol.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Triazolam is combined with Oxprenolol.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Oxprenolol can be increased when used in combination with Trichlormethiazide.]
[A03AB12, mepenzolate, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[S01EB04, demecarium, Demecarium may increase the bradycardic activities of Oxprenolol.]
[N05AB06, trifluoperazine, The serum concentration of Oxprenolol can be increased when it is combined with Trifluoperazine.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Trifluperidol.]
[N05AA05, triflupromazine, The serum concentration of Oxprenolol can be increased when it is combined with Triflupromazine.]
[N04AA01, trihexyphenidyl, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, Oxprenolol may increase the arrhythmogenic activities of Trimebutine.]
[S01ED04, metipranolol, Oxprenolol may increase the arrhythmogenic activities of Metipranolol.]
[R06AD01, trimeprazine, The serum concentration of Oxprenolol can be increased when it is combined with Alimemazine.]
[N03AC02, trimethadione, Trimethadione may increase the arrhythmogenic activities of Oxprenolol.]
[C02BA01, trimethaphan, Trimethaphan may increase the hypotensive activities of Oxprenolol.]
[J01EA01, trimethoprim, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Oxprenolol.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Oxprenolol.]
[R06AC04, tripelennamine, The metabolism of Oxprenolol can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Oxprenolol.]
[A03BB01, butylscopolamine, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[N06AX24, vilazodone, The metabolism of Oxprenolol can be decreased when combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Oxprenolol.]
[C09CA09, azilsartan medoxomil, Oxprenolol may increase the hypotensive activities of Azilsartan medoxomil.]
[M03AA02, tubocurarine, Tubocurarine may increase the bradycardic activities of Oxprenolol.]
[S01AA05, tyrothricin, Tyrothricin may increase the bradycardic activities of Oxprenolol.]
[L02BX03, abiraterone, The metabolism of Oxprenolol can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The therapeutic efficacy of Linagliptin can be increased when used in combination with Oxprenolol.]
[J05AG05, rilpivirine, The metabolism of Oxprenolol can be decreased when combined with Rilpivirine.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Ezogabine.]
[R03AC18, indacaterol, Oxprenolol may decrease the bronchodilatory activities of Indacaterol.]
[C08DA01, verapamil, The risk or severity of adverse effects can be increased when Verapamil is combined with Oxprenolol.]
[N06AX09, viloxazine, The metabolism of Oxprenolol can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Oxprenolol can be decreased when combined with Vinblastine.]
[C04AX07, vincamine, Oxprenolol may increase the hypotensive activities of Vincamine.]
[S01AA13, fusidic acid, The metabolism of Oxprenolol can be decreased when combined with Fusidic acid.]
[N01AX15, xenon, Xenon may decrease the antihypertensive activities of Oxprenolol.]
[C03BA10, xipamide, Oxprenolol may increase the hypotensive activities of Xipamide.]
[N05AF05, zuclopenthixol, Oxprenolol may increase the orthostatic hypotensive activities of Zuclopenthixol.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Levetiracetam is combined with Oxprenolol.]
[L01EC01, vemurafenib, The metabolism of Oxprenolol can be decreased when combined with Vemurafenib.]
[L01ED01, crizotinib, Crizotinib may increase the bradycardic activities of Oxprenolol.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Oxprenolol is combined with Ziprasidone.]
[G03AC10, drospirenone, The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Oxprenolol.]
[N02BA01, aspirin, Acetylsalicylic acid may decrease the antihypertensive activities of Oxprenolol.]
[L01EJ01, ruxolitinib, Ruxolitinib may increase the bradycardic activities of Oxprenolol.]
[G04BD07, tolterodine, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[C07AB03, atenolol, Atenolol may increase the arrhythmogenic activities of Oxprenolol.]
[L01FA01, rituximab, Oxprenolol may increase the hypotensive activities of Rituximab.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Atracurium.]
[S01FA01, atropine, Atropine may increase the arrhythmogenic activities of Oxprenolol.]
[G04BE10, avanafil, Oxprenolol may increase the hypotensive activities of Avanafil.]
[M03BX01, baclofen, The risk or severity of adverse effects can be increased when Baclofen is combined with Oxprenolol.]
[A08AA11, lorcaserin, The metabolism of Oxprenolol can be decreased when combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Oxprenolol can be increased when it is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Oxprenolol can be decreased when combined with Cobicistat.]
[C01CA18, octopamine, The therapeutic efficacy of Octopamine can be decreased when used in combination with Oxprenolol.]
[L01EX05, regorafenib, Regorafenib may increase the bradycardic activities of Oxprenolol.]
[N05CA04, barbital, Barbital may increase the hypotensive activities of Oxprenolol.]
[C01AA01, acetyldigitoxin, Acetyldigitoxin may increase the arrhythmogenic activities of Oxprenolol.]
[S01GA07, brimonidine, Brimonidine may increase the antihypertensive activities of Oxprenolol.]
[N04BD02, rasagiline, Rasagiline may increase the hypotensive activities of Oxprenolol.]
[C08CA13, lercanidipine, Lercanidipine may increase the arrhythmogenic activities of Oxprenolol.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Mosapride.]
[N06DA02, donepezil, Donepezil may increase the bradycardic activities of Oxprenolol.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.]
[L04AA29, tofacitinib, Oxprenolol may increase the bradycardic activities of Tofacitinib.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Oxprenolol.]
[R06AC06, thonzylamine, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, The metabolism of Oxprenolol can be decreased when combined with Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Diethyl ether.]
[H01CB05, pasireotide, Oxprenolol may increase the bradycardic activities of Pasireotide.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be decreased when combined with Oxprenolol.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Oxprenolol.]
[C04AX11, bencyclane, Oxprenolol may increase the arrhythmogenic activities of Bencyclane.]
[A10BH04, alogliptin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Oxprenolol.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Oxprenolol can be decreased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Oxprenolol can be increased when used in combination with Bendroflumethiazide.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Pomalidomide.]
[G03XC05, ospemifene, The metabolism of Oxprenolol can be decreased when combined with Ospemifene.]
[N02BA10, benorilate, Benorilate may decrease the antihypertensive activities of Oxprenolol.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Benperidol.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Oxprenolol.]
[A06AX06, tegaserod, The metabolism of Oxprenolol can be decreased when combined with Tegaserod.]
[H03AA04, tiratricol, The therapeutic efficacy of Tiratricol can be decreased when used in combination with Oxprenolol.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be increased when used in combination with Oxprenolol.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Benzocaine is combined with Oxprenolol.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be increased when used in combination with Oxprenolol.]
[M01AH01, celecoxib, Celecoxib may decrease the antihypertensive activities of Oxprenolol.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Naratriptan is combined with Oxprenolol.]
[L04AA18, everolimus, The metabolism of Oxprenolol can be decreased when combined with Everolimus.]
[N04AC01, benztropine, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[R02AX03, benzydamine, Benzydamine may decrease the antihypertensive activities of Oxprenolol.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Levomilnacipran.]
[C08EA02, bepridil, Bepridil may increase the arrhythmogenic activities of Oxprenolol.]
[C02KX05, riociguat, Oxprenolol may increase the hypotensive activities of Riociguat.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be increased when used in combination with Oxprenolol.]
[C02KX04, macitentan, Oxprenolol may increase the hypotensive activities of Macitentan.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Oxprenolol.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Vortioxetine.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Eslicarbazepine.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Oxprenolol.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Oxprenolol.]
[C01CA27, droxidopa, Oxprenolol may decrease the bronchodilatory activities of Droxidopa.]
[C07AB04, acebutolol, Acebutolol may increase the arrhythmogenic activities of Oxprenolol.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Tasimelteon.]
[L04AA32, apremilast, The metabolism of Oxprenolol can be increased when combined with Apremilast.]
[A16AA06, betaine, Betaine may increase the bradycardic activities of Oxprenolol.]
[S01ED02, betaxolol, Betaxolol may increase the arrhythmogenic activities of Oxprenolol.]
[C02CC01, bethanidine, The therapeutic efficacy of Bethanidine can be decreased when used in combination with Oxprenolol.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be increased when used in combination with Oxprenolol.]
[L04AC11, siltuximab, The metabolism of Oxprenolol can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, Oxprenolol may increase the bradycardic activities of Ceritinib.]
[A03BA03, hyoscyamine, Hyoscyamine may increase the arrhythmogenic activities of Oxprenolol.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Alfaxalone.]
[A10BK03, empagliflozin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Oxprenolol.]
[R03AC19, olodaterol, Oxprenolol may decrease the bronchodilatory activities of Olodaterol.]
[S01EE02, unoprostone, Oxprenolol may increase the hypotensive activities of Unoprostone.]
[D11AA01, glycopyrronium, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The metabolism of Oxprenolol can be decreased when combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Oxprenolol can be decreased when combined with Oritavancin.]
[N05AA04, acepromazine, The serum concentration of Oxprenolol can be increased when it is combined with Acepromazine.]
[V04CX03, methacholine, Oxprenolol may increase the bronchoconstrictory activities of Methacholine.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be increased when used in combination with Oxprenolol.]
[N04AA02, biperiden, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Oxprenolol.]
[S03AA06, gentamicin, The serum concentration of Gentamicin can be increased when it is combined with Oxprenolol.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Oxprenolol.]
[N06AX11, mirtazapine, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Oxprenolol can be increased when combined with Secukinumab.]
[L01XH03, panobinostat, The metabolism of Oxprenolol can be decreased when combined with Panobinostat.]
[N02BE01, acetaminophen, The metabolism of Acetaminophen can be decreased when combined with Oxprenolol.]
[A03AA09, difemerine, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[C01EB17, ivabradine, Oxprenolol may increase the bradycardic activities of Ivabradine.]
[J05AP06, asunaprevir, The metabolism of Oxprenolol can be decreased when combined with Asunaprevir.]
[N05AX16, brexpiprazole, Oxprenolol may increase the orthostatic hypotensive activities of Brexpiprazole.]
[A04AD14, rolapitant, The metabolism of Oxprenolol can be decreased when combined with Rolapitant.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Cariprazine.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be increased when used in combination with Oxprenolol.]
[M02AA25, aceclofenac, Aceclofenac may decrease the antihypertensive activities of Oxprenolol.]
[M01AB11, acemetacin, Acemetacin may decrease the antihypertensive activities of Oxprenolol.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Oxprenolol.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be increased when used in combination with Oxprenolol.]
[N05AB07, acetophenazine, The serum concentration of Oxprenolol can be increased when it is combined with Acetophenazine.]
[A02BC03, lansoprazole, The metabolism of Oxprenolol can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Oxprenolol.]
[J02AC05, isavuconazole, The metabolism of Oxprenolol can be decreased when combined with Isavuconazole.]
[B01AC27, selexipag, Oxprenolol may increase the hypotensive activities of Selexipag.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be increased when used in combination with Oxprenolol.]
[G04CA01, alfuzosin, Alfuzosin may increase the hypotensive activities of Oxprenolol.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Aprobarbital is combined with Oxprenolol.]
[M01AE16, alminoprofen, Alminoprofen may decrease the antihypertensive activities of Oxprenolol.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Brivaracetam.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Bromazepam is combined with Oxprenolol.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Oxprenolol.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Oxprenolol.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Amineptine.]
[C08CA01, amlodipine, Amlodipine may increase the arrhythmogenic activities of Oxprenolol.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Aniracetam.]
[C03CA02, bumetanide, The risk or severity of adverse effects can be increased when Bumetanide is combined with Oxprenolol.]
[N01BB01, bupivacaine, The serum concentration of Bupivacaine can be increased when it is combined with Oxprenolol.]
[C07AA19, bupranolol, Oxprenolol may increase the arrhythmogenic activities of Bupranolol.]
[N07BC01, buprenorphine, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Oxprenolol.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Oxprenolol.]
[N06DA03, rivastigmine, Oxprenolol may increase the bradycardic activities of Rivastigmine.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Oxprenolol.]
[S01GX07, azelastine, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Oxprenolol can be decreased when combined with Rucaparib.]
[A07EC04, balsalazide, Balsalazide may decrease the antihypertensive activities of Oxprenolol.]
[R03CC12, bambuterol, Oxprenolol may decrease the bronchodilatory activities of Bambuterol.]
[R03DA08, bamifylline, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Bamifylline.]
[N07XX16, deutetrabenazine, The metabolism of Deutetrabenazine can be decreased when combined with Oxprenolol.]
[N02BF02, pregabalin, The therapeutic efficacy of Oxprenolol can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Beclamide.]
[N06BC01, caffeine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Caffeine.]
[C09AA07, benazepril, Benazepril may increase the hypotensive activities of Oxprenolol.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be increased when used in combination with Oxprenolol.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Oxprenolol.]
[A12AA04, calcium carbonate, The therapeutic efficacy of Oxprenolol can be decreased when used in combination with Calcium carbonate.]
[G04BA03, calcium chloride, The therapeutic efficacy of Oxprenolol can be decreased when used in combination with Calcium chloride.]
[J01XX08, linezolid, Linezolid may increase the hypotensive activities of Oxprenolol.]
[J05AE09, tipranavir, The metabolism of Oxprenolol can be decreased when combined with Tipranavir.]
[D11AX03, calcium gluconate, The therapeutic efficacy of Oxprenolol can be decreased when used in combination with Calcium gluconate.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Oxprenolol.]
[L04AB02, infliximab, The metabolism of Oxprenolol can be increased when combined with Infliximab.]
[A12AA01, calcium phosphate, The therapeutic efficacy of Oxprenolol can be decreased when used in combination with Calcium Phosphate.]
[N04BD03, safinamide, Safinamide may increase the hypotensive activities of Oxprenolol.]
[N07AB02, bethanechol, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Bethanechol.]
[P03AC02, bioallethrin, Oxprenolol may increase the arrhythmogenic activities of Bioallethrin.]
[S01EB09, acetylcholine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Acetylcholine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Oxprenolol.]
[C07AB07, bisoprolol, The risk or severity of adverse effects can be increased when Bisoprolol is combined with Oxprenolol.]
[R03AC17, bitolterol, Oxprenolol may decrease the bronchodilatory activities of Bitolterol.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Efavirenz is combined with Oxprenolol.]
[C07AA17, bopindolol, The metabolism of Bopindolol can be decreased when combined with Oxprenolol.]
[N04AA11, bornaprine, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Nesiritide.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Brotizolam.]
[C03DA03, canrenone, The risk or severity of hyperkalemia can be increased when Oxprenolol is combined with Canrenone.]
[C04AX20, buflomedil, Buflomedil may decrease the antihypertensive activities of Oxprenolol.]
[M01AB07, bumadizone, Bumadizone may decrease the antihypertensive activities of Oxprenolol.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Butobarbital is combined with Oxprenolol.]
[J05AX18, letermovir, The metabolism of Letermovir can be decreased when combined with Oxprenolol.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Butriptyline.]
[C01AA02, acetyldigoxins, Oxprenolol may increase the arrhythmogenic activities of Acetyldigoxin.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be increased when used in combination with Oxprenolol.]
[N01BX04, capsaicin, Capsaicin may increase the bradycardic activities of Oxprenolol.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be increased when used in combination with Oxprenolol.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Vinylbital.]
[C09AA01, captopril, Captopril may increase the hypotensive activities of Oxprenolol.]
[S01EB02, carbachol, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Carbamoylcholine.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be increased when Carbamazepine is combined with Oxprenolol.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Oxprenolol can be decreased when used in combination with Calcium polycarbophil.]
[A03AA03, camylofine, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Oxprenolol.]
[C07AG02, carvedilol, Carvedilol may increase the arrhythmogenic activities of Oxprenolol.]
[B02BX09, fostamatinib, Fostamatinib may increase the antihypertensive activities of Oxprenolol.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Oxprenolol.]
[L01EC03, encorafenib, The metabolism of Encorafenib can be decreased when combined with Oxprenolol.]
[C07AB08, celiprolol, Oxprenolol may increase the arrhythmogenic activities of Celiprolol.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Oxprenolol.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Oxprenolol.]
[N03AX17, stiripentol, The metabolism of Oxprenolol can be decreased when combined with Stiripentol.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Oxprenolol.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Oxprenolol.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Carbromal.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be increased when used in combination with Oxprenolol.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Oxprenolol.]
[R06AA06, chlorphenoxamine, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, Lornoxicam may decrease the antihypertensive activities of Oxprenolol.]
[R03DA02, oxtriphylline, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Oxtriphylline.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Oxprenolol.]
[R03BB08, revefenacin, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L04AA39, emapalumab, The metabolism of Oxprenolol can be increased when combined with Emapalumab.]
[C01BG07, cifenline, Oxprenolol may increase the arrhythmogenic activities of Cibenzoline.]
[C09AA08, cilazapril, Cilazapril may increase the hypotensive activities of Oxprenolol.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Oxprenolol.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Cinitapride.]
[S01ED05, carteolol, Oxprenolol may increase the arrhythmogenic activities of Carteolol.]
[P02BX04, triclabendazole, The metabolism of Triclabendazole can be decreased when combined with Oxprenolol.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Esketamine.]
[L04AA42, siponimod, Siponimod may decrease the antihypertensive activities of Oxprenolol.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Brexanolone.]
[N05BA09, clobazam, The metabolism of Oxprenolol can be decreased when combined with Clobazam.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Cloxazolam is combined with Oxprenolol.]
[V03AE07, calcium acetate, The therapeutic efficacy of Oxprenolol can be decreased when used in combination with Calcium acetate.]
[C09CA06, candesartan, Oxprenolol may increase the hypotensive activities of Candesartan.]
[L04AB01, etanercept, The metabolism of Oxprenolol can be increased when combined with Etanercept.]
[N05AA06, cyamemazine, The serum concentration of Oxprenolol can be increased when it is combined with Cyamemazine.]
[C03BX03, cicletanine, Oxprenolol may increase the arrhythmogenic activities of Cicletanine.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Oxprenolol.]
[L01EJ02, fedratinib, The metabolism of Oxprenolol can be decreased when combined with Fedratinib.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Oxprenolol is combined with Entrectinib.]
[N07XX11, pitolisant, Oxprenolol may increase the QTc-prolonging activities of Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Oxprenolol.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Oxprenolol.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Oxprenolol can be increased when used in combination with Cyclothiazide.]
[G04BE04, yohimbine, The therapeutic efficacy of Oxprenolol can be increased when used in combination with Yohimbine.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be increased when used in combination with Oxprenolol.]
[N02CC08, lasmiditan, The risk or severity of adverse effects can be increased when Lasmiditan is combined with Oxprenolol.]
[A16AX16, givosiran, The serum concentration of Oxprenolol can be increased when it is combined with Givosiran.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Oxprenolol.]
[R06AB02, dexchlorpheniramine, The metabolism of Dexchlorpheniramine can be decreased when combined with Oxprenolol.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Dezocine is combined with Oxprenolol.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Lemborexant.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Lumateperone.]
[M01AX21, diacetylrhein, The metabolism of Oxprenolol can be decreased when combined with Diacerein.]
[H02CA02, osilodrostat, The metabolism of Oxprenolol can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Amprenavir can be decreased when combined with Oxprenolol.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Frovatriptan is combined with Oxprenolol.]
[G04CB02, dutasteride, Dutasteride may decrease the antihypertensive activities of Oxprenolol.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Oxprenolol.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Difenoxin is combined with Oxprenolol.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Oxprenolol.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Oxprenolol.]
[M01AH02, rofecoxib, Rofecoxib may decrease the antihypertensive activities of Oxprenolol.]
[C08CA16, clevidipine, Oxprenolol may increase the arrhythmogenic activities of Clevidipine.]
[C01BD07, dronedarone, Dronedarone may increase the bradycardic activities of Oxprenolol.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Valpromide.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Oxprenolol.]
[C02AA06, methoserpidine, Oxprenolol may increase the hypotensive activities of Methoserpidine.]
[A03AA08, dihexyverine, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Opicapone.]
[C01CA14, dopexamine, The therapeutic efficacy of Dopexamine can be decreased when used in combination with Oxprenolol.]
[G04BD09, trospium, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, Droxicam may decrease the antihypertensive activities of Oxprenolol.]
[L01EX22, selpercatinib, Selpercatinib may decrease the antihypertensive activities of Oxprenolol.]
[M02AA27, dexketoprofen, Dexketoprofen may decrease the antihypertensive activities of Oxprenolol.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Chlormezanone is combined with Oxprenolol.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Dyclonine is combined with Oxprenolol.]
[C08CA17, levamlodipine, The risk or severity of bradycardia can be increased when Levamlodipine is combined with Oxprenolol.]
[P01BB01, proguanil, The metabolism of Oxprenolol can be decreased when combined with Proguanil.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Remimazolam.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Oxprenolol is combined with Oliceridine.]
[P01BA01, chloroquine, The metabolism of Oxprenolol can be decreased when combined with Chloroquine.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Oxprenolol can be increased when used in combination with Chlorothiazide.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Oxprenolol.]
[N05AA01, chlorpromazine, The metabolism of Oxprenolol can be decreased when combined with Chlorpromazine.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Oxprenolol.]
[N05AF03, chlorprothixene, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the hypotensive activities of Oxprenolol.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Oxprenolol.]
[A11CC05, cholecalciferol, The metabolism of Oxprenolol can be decreased when combined with Cholecalciferol.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Etifoxine.]
[N02BA07, ethenzamide, Ethenzamide may decrease the antihypertensive activities of Oxprenolol.]
[N02BA03, choline salicylate, The serum concentration of Choline salicylate can be increased when it is combined with Oxprenolol.]
[N06BX18, vinpocetine, Oxprenolol may increase the arrhythmogenic activities of Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Oxprenolol.]
[M01AB08, etodolac, Etodolac may decrease the antihypertensive activities of Oxprenolol.]
[M02AA06, etofenamate, Etofenamate may decrease the antihypertensive activities of Oxprenolol.]
[B06AC06, berotralstat, The metabolism of Oxprenolol can be decreased when combined with Berotralstat.]
[M09AA01, hydroquinine, Oxprenolol may increase the arrhythmogenic activities of Hydroquinine.]
[L01FX21, naxitamab, Naxitamab may decrease the antihypertensive activities of Oxprenolol.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Vericiguat.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Felbamate is combined with Oxprenolol.]
[M01AE05, fenbufen, Fenbufen may decrease the antihypertensive activities of Oxprenolol.]
[N06BA10, fenethylline, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Fenethylline.]
[C01CA19, fenoldopam, Fenoldopam may increase the hypotensive activities of Oxprenolol.]
[N06BA08, fenozolone, Fenozolone may decrease the antihypertensive activities of Oxprenolol.]
[G04CB01, finasteride, Finasteride may decrease the antihypertensive activities of Oxprenolol.]
[R03CC15, formoterol, Oxprenolol may decrease the bronchodilatory activities of Formoterol.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be increased when used in combination with Oxprenolol.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Oxprenolol.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The metabolism of Oxprenolol can be decreased when combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, The therapeutic efficacy of Oxprenolol can be decreased when used in combination with Dasiglucagon.]
[A02BA01, cimetidine, The metabolism of Oxprenolol can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Oxprenolol.]
[N07CA02, cinnarizine, Cinnarizine may increase the arrhythmogenic activities of Oxprenolol.]
[L01XA01, cisplatin, The serum concentration of Cisplatin can be increased when it is combined with Oxprenolol.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Citalopram.]
[C03DA05, finerenone, The risk or severity of hyperkalemia can be increased when Oxprenolol is combined with Finerenone.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Oxprenolol is combined with Mobocertinib.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Oxprenolol.]
[M01AG01, mefenamic acid, Mefenamic acid may decrease the antihypertensive activities of Oxprenolol.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be increased when used in combination with Oxprenolol.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be increased when used in combination with Oxprenolol.]
[R03CC13, clenbuterol, Oxprenolol may decrease the bronchodilatory activities of Clenbuterol.]
[A12AA02, calcium glubionate, The therapeutic efficacy of Oxprenolol can be decreased when used in combination with Calcium glubionate anhydrous.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be increased when St. John's Wort is combined with Oxprenolol.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Oxprenolol.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Oxprenolol.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Oxprenolol.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Clonazepam is combined with Oxprenolol.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Oxprenolol.]
[A10BX16, tirzepatide, The therapeutic efficacy of Tirzepatide can be increased when used in combination with Oxprenolol.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Clotiazepam is combined with Oxprenolol.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Ondansetron is combined with Oxprenolol.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Granisetron is combined with Oxprenolol.]
[N05AH02, clozapine, The metabolism of Oxprenolol can be decreased when combined with Clozapine.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be increased when used in combination with Oxprenolol.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be increased when used in combination with Oxprenolol.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Oxprenolol.]
[S02DA02, cocaine, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, Oxprenolol may increase the sedative activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Oxprenolol can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, Proquazone may decrease the antihypertensive activities of Oxprenolol.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Oxprenolol.]
[M03AC05, hexafluorenium, Hexafluronium may increase the bradycardic activities of Oxprenolol.]
[A03AB10, hexocyclium, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[C01BA13, hydroquinidine, Oxprenolol may increase the arrhythmogenic activities of Hydroquinidine.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Desflurane is combined with Oxprenolol.]
[A04AA03, tropisetron, Oxprenolol may increase the arrhythmogenic activities of Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Ifenprodil.]
[A10BX03, nateglinide, The therapeutic efficacy of Nateglinide can be increased when used in combination with Oxprenolol.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may decrease the antihypertensive activities of Oxprenolol.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be increased when used in combination with Oxprenolol.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be increased when used in combination with Oxprenolol.]
[R03BA08, ciclesonide, The metabolism of Ciclesonide can be decreased when combined with Oxprenolol.]
[B01AC10, indobufen, Indobufen may decrease the antihypertensive activities of Oxprenolol.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Desloratadine is combined with Oxprenolol.]
[M01AH03, valdecoxib, Valdecoxib may decrease the antihypertensive activities of Oxprenolol.]
[H01AX01, pegvisomant, Pegvisomant may increase the bradycardic activities of Oxprenolol.]
[C01AA06, lanatoside C, Oxprenolol may increase the bradycardic activities of Lanatoside C.]
[A03AX10, isometheptene, The therapeutic efficacy of Isometheptene can be decreased when used in combination with Oxprenolol.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Almotriptan is combined with Oxprenolol.]
[M01AH04, parecoxib, Parecoxib may decrease the antihypertensive activities of Oxprenolol.]
[J02AC02, itraconazole, The risk or severity of hyperkalemia can be increased when Itraconazole is combined with Oxprenolol.]
[B01AB12, bemiparin, The risk or severity of hyperkalemia can be increased when Oxprenolol is combined with Bemiparin.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Ketazolam.]
[M01AA06, kebuzone, Kebuzone may decrease the antihypertensive activities of Oxprenolol.]
[L01EA01, imatinib, The serum concentration of Oxprenolol can be increased when it is combined with Imatinib.]
[S01EE04, travoprost, Travoprost may increase the hypotensive activities of Oxprenolol.]
[S01EE03, bimatoprost, Bimatoprost may increase the hypotensive activities of Oxprenolol.]
[C08CA09, lacidipine, Oxprenolol may increase the hypotensive activities of Lacidipine.]
[N03AX09, lamotrigine, Lamotrigine may increase the arrhythmogenic activities of Oxprenolol.]
[N07BC04, lofexidine, The therapeutic efficacy of Oxprenolol can be increased when used in combination with Lofexidine.]
[M01AB09, lonazolac, Lonazolac may decrease the antihypertensive activities of Oxprenolol.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Lormetazepam.]
[M02AA31, loxoprofen, Loxoprofen may decrease the antihypertensive activities of Oxprenolol.]
[C09AA03, lisinopril, Lisinopril may increase the hypotensive activities of Oxprenolol.]
[C08CA11, manidipine, Oxprenolol may increase the arrhythmogenic activities of Manidipine.]
[A03AA04, mebeverine, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Medifoxamine.]
[A08AA09, mefenorex, Mefenorex may decrease the antihypertensive activities of Oxprenolol.]
[C07AA14, mepindolol, The metabolism of Mepindolol can be decreased when combined with Oxprenolol.]
[R06AD07, mequitazine, The metabolism of Mequitazine can be decreased when combined with Oxprenolol.]
[C01EB10, adenosine, Adenosine may increase the arrhythmogenic activities of Oxprenolol.]
[N04AA03, methixene, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[C04AX01, cyclandelate, Oxprenolol may increase the arrhythmogenic activities of Cyclandelate.]
[R03CB02, methoxyphenamine, The therapeutic efficacy of Oxprenolol can be decreased when used in combination with Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Cyclizine is combined with Oxprenolol.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Cyclobarbital.]
[C03DA04, eplerenone, Eplerenone may increase the hypotensive activities of Oxprenolol.]
[N05AD03, metylperon, Oxprenolol may increase the arrhythmogenic activities of Melperone.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Oxprenolol can be increased when used in combination with Cyclopenthiazide.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be increased when used in combination with Oxprenolol.]
[N06AX07, minaprine, Minaprine may increase the bradycardic activities of Oxprenolol.]
[S01XA18, cyclosporine, The metabolism of Oxprenolol can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the hypotensive activities of Oxprenolol.]
[R06AX02, cyproheptadine, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C09AA13, moexipril, Moexipril may increase the hypotensive activities of Oxprenolol.]
[M02AA02, mofebutazone, Mofebutazone may decrease the antihypertensive activities of Oxprenolol.]
[M01AX22, morniflumate, Morniflumate may decrease the antihypertensive activities of Oxprenolol.]
[C03XA02, conivaptan, The risk or severity of adverse effects can be increased when Conivaptan is combined with Oxprenolol.]
[C02AC05, moxonidine, The therapeutic efficacy of Moxonidine can be decreased when used in combination with Oxprenolol.]
[G04BE09, vardenafil, Vardenafil may increase the antihypertensive activities of Oxprenolol.]
[M01AH05, etoricoxib, Etoricoxib may decrease the antihypertensive activities of Oxprenolol.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Dantrolene is combined with Oxprenolol.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Deanol.]
[C02CC04, debrisoquin, The metabolism of Debrisoquine can be decreased when combined with Oxprenolol.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.]
[M01AX01, nabumetone, Nabumetone may decrease the antihypertensive activities of Oxprenolol.]
[B05XA15, potassium lactate, Potassium lactate may increase the hyperkalemic activities of Oxprenolol.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Nordazepam.]
[C07AB12, nebivolol, Oxprenolol may increase the arrhythmogenic activities of Nebivolol.]
[N06AX06, nefazodone, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Niaprazine.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Oxprenolol.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Tiagabine is combined with Oxprenolol.]
[C01CA23, theodrenaline, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Theodrenaline.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Oxprenolol.]
[C01CA05, norfenefrine, The therapeutic efficacy of Norfenefrine can be decreased when used in combination with Oxprenolol.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Normethadone.]
[N06AB10, escitalopram, The serum concentration of Oxprenolol can be increased when it is combined with Escitalopram.]
[G04BD08, solifenacin, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[A07EC03, olsalazine, Olsalazine may decrease the antihypertensive activities of Oxprenolol.]
[N06AA01, desipramine, The metabolism of Oxprenolol can be decreased when combined with Desipramine.]
[C01AA07, deslanoside, Deslanoside may increase the arrhythmogenic activities of Oxprenolol.]
[H01BA02, desmopressin, Desmopressin may decrease the antihypertensive activities of Oxprenolol.]
[C09XA02, aliskiren, Oxprenolol may increase the hypotensive activities of Aliskiren.]
[L01XA03, oxaliplatin, The serum concentration of Oxaliplatin can be increased when it is combined with Oxprenolol.]
[M01AE12, oxaprozin, Oxaprozin may decrease the antihypertensive activities of Oxprenolol.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Oxprenolol.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Oxiracetam.]
[N04AA08, dexetimide, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be decreased when combined with Oxprenolol.]
[A03AA01, oxyphencyclimine, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Oxprenolol can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Gefitinib can be decreased when combined with Oxprenolol.]
[N06BA02, dextroamphetamine, The therapeutic efficacy of Oxprenolol can be decreased when used in combination with Amphetamine.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Oxprenolol.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Oxprenolol.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Dextromoramide is combined with Oxprenolol.]
[N06AB05, paroxetine, The metabolism of Oxprenolol can be decreased when combined with Paroxetine.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Diamorphine is combined with Oxprenolol.]
[C04AD01, pentifylline, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Pentifylline.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Diazepam is combined with Oxprenolol.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Phenacemide is combined with Oxprenolol.]
[V03AH01, diazoxide, Diazoxide may increase the hypotensive activities of Oxprenolol.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Phensuximide is combined with Oxprenolol.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Dibenzepin.]
[S02DA04, dibucaine, Cinchocaine may increase the bradycardic activities of Oxprenolol.]
[S01EC02, dichlorphenamide, The risk or severity of adverse effects can be increased when Diclofenamide is combined with Oxprenolol.]
[S01BC03, diclofenac, Diclofenac may decrease the antihypertensive activities of Oxprenolol.]
[A03AA07, dicyclomine, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[C02DG01, pinacidil, Oxprenolol may increase the hypotensive activities of Pinacidil.]
[A03AX04, pinaverium, Oxprenolol may increase the arrhythmogenic activities of Pinaverium.]
[A10BG03, pioglitazone, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Oxprenolol.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Pipamperone.]
[A03AB14, pipenzolate, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Oxprenolol.]
[R03CC07, pirbuterol, Oxprenolol may decrease the bronchodilatory activities of Pirbuterol.]
[P02CB02, diethylcarbamazine, Diethylcarbamazine may increase the bradycardic activities of Oxprenolol.]
[A08AA03, diethylpropion, The therapeutic efficacy of Oxprenolol can be decreased when used in combination with Diethylpropion.]
[C08CA03, isradipine, Isradipine may increase the arrhythmogenic activities of Oxprenolol.]
[A03AB11, poldine, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, Diflunisal may decrease the antihypertensive activities of Oxprenolol.]
[C01AA04, digitoxin, Digitoxin may increase the arrhythmogenic activities of Oxprenolol.]
[C01AA05, digoxin, Digoxin may increase the arrhythmogenic activities of Oxprenolol.]
[C02DB01, dihydralazine, Oxprenolol may increase the hypotensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, Oxprenolol may increase the vasoconstricting activities of Dihydroergocristine.]
[N02CA01, dihydroergotamine, Oxprenolol may increase the vasoconstricting activities of Dihydroergotamine.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxprenolol.]
[B01AC21, treprostinil, Treprostinil may increase the hypotensive activities of Oxprenolol.]
[H03BC01, potassium perchlorate, Potassium perchlorate may increase the hyperkalemic activities of Oxprenolol.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Pramocaine.]
[C08DB01, diltiazem, Diltiazem may increase the arrhythmogenic activities of Oxprenolol.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Oxprenolol.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Pridinol.]
[R06AB03, dimethindene, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[R03CC08, procaterol, Oxprenolol may decrease the bronchodilatory activities of Procaterol.]
[M02AX03, dimethyl sulfoxide, The metabolism of Oxprenolol can be decreased when combined with Dimethyl sulfoxide.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Progabide is combined with Oxprenolol.]
[N06BC02, propentofylline, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Propentofylline.]
[N02BB04, propyphenazone, Propyphenazone may decrease the antihypertensive activities of Oxprenolol.]
[M01AB14, proglumetacin, Proglumetacin may decrease the antihypertensive activities of Oxprenolol.]
[R03DA03, proxyphylline, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Proxyphylline.]
[R06AA02, diphenhydramine, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Oxprenolol.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Quazepam.]
[C09AA06, quinapril, Quinapril may increase the hypotensive activities of Oxprenolol.]
[B01AC07, dipyridamole, Dipyridamole may increase the bradycardic activities of Oxprenolol.]
[N06BA11, dexmethylphenidate, Dexmethylphenidate may decrease the antihypertensive activities of Oxprenolol.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Quinupramine.]
[A03FA02, cisapride, The metabolism of Oxprenolol can be decreased when combined with Cisapride.]
[C09AA05, ramipril, Ramipril may increase the hypotensive activities of Oxprenolol.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Oxprenolol.]
[R03CC14, reproterol, The therapeutic efficacy of Reproterol can be decreased when used in combination with Oxprenolol.]
[C01BA03, disopyramide, Disopyramide may increase the bradycardic activities of Oxprenolol.]
[N07AA03, distigmine, Distigmine may increase the bradycardic activities of Oxprenolol.]
[S02AA12, rifamycin SV, The metabolism of Oxprenolol can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Oxprenolol can be increased when combined with Rifapentine.]
[D06AX11, rifaximin, The metabolism of Oxprenolol can be increased when combined with Rifaximin.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Oxprenolol.]
[N05AX08, risperidone, Oxprenolol may increase the hypotensive activities of Risperidone.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxprenolol.]
[L01EX01, sunitinib, The therapeutic efficacy of Sunitinib can be increased when used in combination with Oxprenolol.]
[C03XA01, tolvaptan, The risk or severity of hyperkalemia can be increased when Oxprenolol is combined with Tolvaptan.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Oxprenolol.]
[G04BE08, tadalafil, Tadalafil may increase the hypotensive activities of Oxprenolol.]
[S01BC05, ketorolac, Ketorolac may decrease the antihypertensive activities of Oxprenolol.]
[C02KX02, ambrisentan, Oxprenolol may increase the hypotensive activities of Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Oxprenolol can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, Salsalate may decrease the antihypertensive activities of Oxprenolol.]
[R03AC12, salmeterol, Oxprenolol may decrease the bronchodilatory activities of Salmeterol.]
[C01CA07, dobutamine, Oxprenolol may decrease the bronchodilatory activities of Dobutamine.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Oxprenolol.]
[C01CA04, dopamine, The serum concentration of Dopamine can be increased when it is combined with Oxprenolol.]
[N06AA16, dothiepin, The metabolism of Oxprenolol can be decreased when combined with Dosulepin.]
[R07AB01, doxapram, Doxapram may decrease the antihypertensive activities of Oxprenolol.]
[N06AA12, doxepin, Oxprenolol may increase the orthostatic hypotensive activities of Doxepin.]
[L01DB01, doxorubicin, The metabolism of Oxprenolol can be decreased when combined with Doxorubicin.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Sevoflurane is combined with Oxprenolol.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Sibutramine.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Oxprenolol.]
[V03AG05, sodium phosphate, Sodium phosphate, monobasic may increase the hyperkalemic activities of Oxprenolol.]
[C09AA11, spirapril, Spirapril may increase the hypotensive activities of Oxprenolol.]
[R03DA01, dyphylline, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Dyphylline.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Oxprenolol.]
[V04CX07, edrophonium, Edrophonium may increase the bradycardic activities of Oxprenolol.]
[C07AB13, talinolol, Oxprenolol may increase the arrhythmogenic activities of Talinolol.]
[M01AC02, tenoxicam, Tenoxicam may decrease the antihypertensive activities of Oxprenolol.]
[G04CA03, terazosin, Oxprenolol may increase the orthostatic hypotensive activities of Terazosin.]
[D01BA02, terbinafine, The metabolism of Oxprenolol can be decreased when combined with Terbinafine.]
[G04BD05, terodiline, Oxprenolol may increase the arrhythmogenic activities of Terodiline.]
[C07AA16, tertatolol, Oxprenolol may increase the arrhythmogenic activities of Tertatolol.]
[S01GA02, tetrahydrozoline, The therapeutic efficacy of Tetryzoline can be decreased when used in combination with Oxprenolol.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Thiopropazate.]
[G04BD01, emepronium, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Tianeptine.]
[C09AA02, enalapril, Enalapril may increase the hypotensive activities of Oxprenolol.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Tofisopam.]
[M01AG02, tolfenamic acid, Tolfenamic acid may decrease the antihypertensive activities of Oxprenolol.]
[N06AG03, toloxatone, Toloxatone may increase the hypotensive activities of Oxprenolol.]
[N06BA09, atomoxetine, The metabolism of Atomoxetine can be decreased when combined with Oxprenolol.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Oxprenolol.]
[C03CA04, torsemide, Torasemide may increase the hypotensive activities of Oxprenolol.]
[R01AA09, tramazoline, Tramazoline may decrease the antihypertensive activities of Oxprenolol.]
[C09AA10, trandolapril, Trandolapril may increase the hypotensive activities of Oxprenolol.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Oxprenolol.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Triclofos.]
[A03AB08, tridihexethyl, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Oxprenolol.]
[N04AA12, tropatepine, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[R03CC11, tulobuterol, The therapeutic efficacy of Tulobuterol can be decreased when used in combination with Oxprenolol.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Oxprenolol.]
[C02CA06, urapidil, Oxprenolol may increase the orthostatic hypotensive activities of Urapidil.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Veralipride.]
[L01CA04, vinorelbine, The metabolism of Oxprenolol can be decreased when combined with Vinorelbine.]
[S01FB02, ephedrine, The therapeutic efficacy of Ephedrine can be decreased when used in combination with Oxprenolol.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Epinastine is combined with Oxprenolol.]
[N06AX16, venlafaxine, The metabolism of Oxprenolol can be decreased when combined with Venlafaxine.]
[C01CX07, xamoterol, The therapeutic efficacy of Xamoterol can be decreased when used in combination with Oxprenolol.]
[S01GA03, xylometazoline, Oxprenolol may increase the arrhythmogenic activities of Xylometazoline.]
[C08CA12, mepirodipine, Oxprenolol may increase the antihypertensive activities of Barnidipine.]
[S01EA01, epinephrine, Oxprenolol may decrease the bronchodilatory activities of Epinephrine.]
[C09AA15, zofenopril, Oxprenolol may increase the hypotensive activities of Zofenopril.]
[N05CF02, zolpidem, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, Zomepirac may decrease the antihypertensive activities of Oxprenolol.]
[N03AX15, zonisamide, Zonisamide may increase the arrhythmogenic activities of Oxprenolol.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be increased when used in combination with Oxprenolol.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Zotepine.]
[C02AC02, guanfacine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Oxprenolol.]
[B01AC11, iloprost, Iloprost may increase the hypotensive activities of Oxprenolol.]
[C01BG01, moricizine, Moricizine may increase the arrhythmogenic activities of Oxprenolol.]
[G02AB03, ergonovine, The therapeutic efficacy of Ergometrine can be decreased when used in combination with Oxprenolol.]
[C04AE01, ergoloid mesylates, USP, Oxprenolol may increase the vasoconstricting activities of Ergoloid mesylate.]
[N02CA02, ergotamine, Oxprenolol may increase the vasoconstricting activities of Ergotamine.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Oxprenolol.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Estazolam is combined with Oxprenolol.]
[H05BX01, cinacalcet, The metabolism of Oxprenolol can be decreased when combined with Cinacalcet.]
[J04AK02, ethambutol, The metabolism of Oxprenolol can be decreased when combined with Ethambutol.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Oxprenolol.]
[C01CA15, gepefrine, The therapeutic efficacy of Oxprenolol can be decreased when used in combination with Gepefrine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxprenolol.]
[V03AF05, amifostine, Oxprenolol may increase the hypotensive activities of Amifostine.]
[C01BD05, ibutilide, Ibutilide may increase the arrhythmogenic activities of Oxprenolol.]
[N04AA05, profenamine, Profenamine may increase the bradycardic activities of Oxprenolol.]
[N03AD01, ethosuximide, Ethosuximide may increase the arrhythmogenic activities of Oxprenolol.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Oxprenolol.]
[M01AC06, meloxicam, Meloxicam may decrease the antihypertensive activities of Oxprenolol.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Oxprenolol.]
[C01CA01, etilefrine, The therapeutic efficacy of Etilefrine can be decreased when used in combination with Oxprenolol.]
[N01AX07, etomidate, The therapeutic efficacy of Etomidate can be decreased when used in combination with Oxprenolol.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Sertindole.]
[C01BA05, ajmaline, Ajmaline may increase the arrhythmogenic activities of Oxprenolol.]
[L04AD02, tacrolimus, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Oxprenolol.]
[A02BA04, nizatidine, Nizatidine may increase the bradycardic activities of Oxprenolol.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Oxprenolol.]
[R06AX12, terfenadine, The metabolism of Oxprenolol can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, The metabolism of Oxprenolol can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Oxprenolol can be decreased when combined with Fluvoxamine.]
[C01BB03, tocainide, Tocainide may increase the arrhythmogenic activities of Oxprenolol.]
[C01BC08, encainide, Encainide may increase the arrhythmogenic activities of Oxprenolol.]
[C08CA02, felodipine, Felodipine may increase the arrhythmogenic activities of Oxprenolol.]
[C08EA01, fendiline, Oxprenolol may increase the arrhythmogenic activities of Fendiline.]
[N03AX26, fenfluramine, The risk or severity of adverse effects can be increased when Fenfluramine is combined with Oxprenolol.]
[M01AE04, fenoprofen, Fenoprofen may decrease the antihypertensive activities of Oxprenolol.]
[R03CC04, fenoterol, Oxprenolol may decrease the bronchodilatory activities of Fenoterol.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Fentanyl is combined with Oxprenolol.]
[R03CC02, albuterol, Oxprenolol may decrease the bronchodilatory activities of Salbutamol.]
[L01BB06, clofarabine, The serum concentration of Clofarabine can be increased when it is combined with Oxprenolol.]
[N07AX03, cevimeline, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Cevimeline.]
[G04BD02, flavoxate, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, Flecainide may increase the arrhythmogenic activities of Oxprenolol.]
[N02BG04, floctafenine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Floctafenine.]
[J02AC01, fluconazole, The risk or severity of hyperkalemia can be increased when Fluconazole is combined with Oxprenolol.]
[N07CA03, flunarizine, Oxprenolol may increase the arrhythmogenic activities of Flunarizine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Oxprenolol.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Melitracen.]
[V03AZ01, ethanol, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[N06AB03, fluoxetine, The serum concentration of Oxprenolol can be increased when it is combined with Fluoxetine.]
[N05AF01, flupenthixol, Oxprenolol may increase the orthostatic hypotensive activities of Flupentixol.]
[N05AB02, fluphenazine, The serum concentration of Oxprenolol can be increased when it is combined with Fluphenazine.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Oxprenolol.]
[S01BC04, flurbiprofen, Flurbiprofen may decrease the antihypertensive activities of Oxprenolol.]
[N05AG01, fluspirilene, Oxprenolol may increase the arrhythmogenic activities of Fluspirilene.]
[N06BX17, adrafinil, The therapeutic efficacy of Adrafinil can be decreased when used in combination with Oxprenolol.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Alcuronium.]
[G01AX06, furazolidone, Furazolidone may increase the hypotensive activities of Oxprenolol.]
[J05AE10, darunavir, The metabolism of Oxprenolol can be decreased when combined with Darunavir.]
[C03CA01, furosemide, Furosemide may increase the hypotensive activities of Oxprenolol.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Oxprenolol is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Amisulpride.]
[N06DA04, galantamine, Galantamine may increase the bradycardic activities of Oxprenolol.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Gallamine.]
[C08DA02, gallopamil, Oxprenolol may increase the arrhythmogenic activities of Gallopamil.]
[N03AA04, barbexaclone, Barbexaclone may increase the hypotensive activities of Oxprenolol.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Bifemelane.]
[N04BC06, cabergoline, Oxprenolol may increase the vasoconstricting activities of Cabergoline.]
[C01CA21, cafedrine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Cafedrine.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be increased when used in combination with Oxprenolol.]
[A12AA13, calcium citrate, The therapeutic efficacy of Oxprenolol can be decreased when used in combination with Calcium citrate.]
[A12AA10, calcium gluceptate, The therapeutic efficacy of Oxprenolol can be decreased when used in combination with Calcium glucoheptonate.]
[A12AA05, calcium lactate, The therapeutic efficacy of Oxprenolol can be decreased when used in combination with Calcium lactate.]
[A12AA30, calcium levulinate, The therapeutic efficacy of Oxprenolol can be decreased when used in combination with Calcium levulinate.]
[N03AD03, methsuximide, Oxprenolol may increase the arrhythmogenic activities of Methsuximide.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Alfentanil is combined with Oxprenolol.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be increased when used in combination with Oxprenolol.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be increased when used in combination with Oxprenolol.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be increased when used in combination with Oxprenolol.]
[H04AA01, glucagon, The therapeutic efficacy of Oxprenolol can be decreased when used in combination with Glucagon.]
[N05CM18, dexmedetomidine, The therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Oxprenolol.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Glutethimide is combined with Oxprenolol.]
[C05AE01, nitroglycerin, Nitroglycerin may increase the hypotensive activities of Oxprenolol.]
[C01BD04, dofetilide, Dofetilide may increase the arrhythmogenic activities of Oxprenolol.]
[C02CA04, doxazosin, Oxprenolol may increase the orthostatic hypotensive activities of Doxazosin.]
[H01AB01, thyrotropin alfa, The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Oxprenolol.]
[C07AB09, esmolol, Esmolol may increase the arrhythmogenic activities of Oxprenolol.]
[C09AA09, fosinopril, Fosinopril may increase the hypotensive activities of Oxprenolol.]
[S01EX01, guanethidine, Guanethidine may increase the hypotensive activities of Oxprenolol.]
[P01BX01, halofantrine, The metabolism of Oxprenolol can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Oxprenolol is combined with Haloperidol.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Halothane is combined with Oxprenolol.]
[N05AH04, quetiapine, Quetiapine may increase the hypotensive activities of Oxprenolol.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be increased when used in combination with Oxprenolol.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Iprazochrome.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Allobarbital.]
[C09CA01, losartan, Losartan may increase the arrhythmogenic activities of Oxprenolol.]
[S01XA14, heparin, The risk or severity of hyperkalemia can be increased when Heparin is combined with Oxprenolol.]
[A07EC02, mesalamine, Mesalazine may decrease the antihypertensive activities of Oxprenolol.]
[N05CA16, hexobarbital, Hexobarbital may increase the hypotensive activities of Oxprenolol.]
[R03CC05, hexoprenaline, Oxprenolol may decrease the bronchodilatory activities of Hexoprenaline.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be decreased when combined with Oxprenolol.]
[C08CA10, nilvadipine, Oxprenolol may increase the arrhythmogenic activities of Nilvadipine.]
[M02AA26, nimesulide, Nimesulide may decrease the antihypertensive activities of Oxprenolol.]
[C09AA04, perindopril, Perindopril may increase the hypotensive activities of Oxprenolol.]
[C02DB02, hydralazine, Hydralazine may increase the hypotensive activities of Oxprenolol.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Oxprenolol can be increased when used in combination with Hydrochlorothiazide.]
[R05DA03, hydrocodone, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Oxprenolol can be increased when used in combination with Hydroflumethiazide.]
[B05XA17, potassium acetate, Potassium acetate may increase the hyperkalemic activities of Oxprenolol.]
[S01XA07, aluminum potassium sulfate, Potassium alum may increase the hyperkalemic activities of Oxprenolol.]
[A12BA02, potassium citrate, Potassium citrate may increase the hyperkalemic activities of Oxprenolol.]
[G04BD06, propiverine, Oxprenolol may increase the orthostatic hypotensive activities of Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be decreased when Hydroxychloroquine is combined with Oxprenolol.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Prothipendyl.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Oxprenolol is combined with Hydroxyzine.]
[C02AC06, rilmenidine, The therapeutic efficacy of Rilmenidine can be decreased when used in combination with Oxprenolol.]
[R02AX02, ibuprofen, Ibuprofen may decrease the antihypertensive activities of Oxprenolol.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Oxprenolol.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Oxprenolol.]
[N06AA02, imipramine, The metabolism of Oxprenolol can be decreased when combined with Imipramine.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Oxprenolol.]
[M03BX02, tizanidine, The therapeutic efficacy of Tizanidine can be decreased when used in combination with Oxprenolol.]
[C03BA11, indapamide, The therapeutic efficacy of Indapamide can be increased when used in combination with Oxprenolol.]
[S01BC01, indomethacin, Indomethacin may decrease the antihypertensive activities of Oxprenolol.]
[C02CA02, indoramin, Oxprenolol may increase the orthostatic hypotensive activities of Indoramin.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Milnacipran.]
[A03AA30, piperidolate, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[S01XA28, varenicline, The excretion of Varenicline can be decreased when combined with Oxprenolol.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Articaine.]
[A10BH01, sitagliptin, The therapeutic efficacy of Sitagliptin can be increased when used in combination with Oxprenolol.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Oxprenolol.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Ramelteon is combined with Oxprenolol.]
[R06AE01, buclizine, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be increased when used in combination with Oxprenolol.]
[C10AA06, cerivastatin, The metabolism of Oxprenolol can be decreased when combined with Cerivastatin.]
[C07AA01, alprenolol, Alprenolol may increase the arrhythmogenic activities of Oxprenolol.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Oxprenolol.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Iprindole.]
[N06AF05, iproniazid, Iproniazid may increase the hypotensive activities of Oxprenolol.]
[N05AA07, chlorproethazine, The serum concentration of Oxprenolol can be increased when it is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the hypotensive activities of Oxprenolol.]
[S01EC03, dorzolamide, Dorzolamide may increase the hypotensive activities of Oxprenolol.]
[R03CC06, isoetharine, Oxprenolol may decrease the bronchodilatory activities of Isoetharine.]
[C09AA16, imidapril, Oxprenolol may increase the hypotensive activities of Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Oxprenolol.]
[S01EB07, isoflurophate, Isoflurophate may increase the bradycardic activities of Oxprenolol.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Oxprenolol.]
[R03CB01, isoproterenol, Oxprenolol may decrease the bronchodilatory activities of Isoprenaline.]
[A10BJ01, exenatide, The therapeutic efficacy of Exenatide can be increased when used in combination with Oxprenolol.]
[C01DA14, isosorbide mononitrate, Oxprenolol may increase the vasodilatory activities of Isosorbide mononitrate.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Isosorbide dinitrate is combined with Oxprenolol.]
[C04AA01, isoxsuprine, The therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Oxprenolol.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Oxprenolol.]
[L04AC07, tocilizumab, The metabolism of Oxprenolol can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, Ketamine may increase the bradycardic activities of Oxprenolol.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Ketanserin.]
[J02AB02, ketoconazole, The metabolism of Oxprenolol can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, Oxprenolol may increase the orthostatic hypotensive activities of Olanzapine.]
[M02AA10, ketoprofen, Ketoprofen may decrease the antihypertensive activities of Oxprenolol.]
[L04AA24, abatacept, The metabolism of Oxprenolol can be increased when combined with Abatacept.]
[C01CA22, arbutamine, Oxprenolol may decrease the bronchodilatory activities of Arbutamine.]
[N04BC09, rotigotine, Oxprenolol may increase the sedative activities of Rotigotine.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may decrease the antihypertensive activities of Oxprenolol.]
[C07AG01, labetalol, Oxprenolol may increase the orthostatic hypotensive activities of Labetalol.]
[N04BB01, amantadine, The serum concentration of Amantadine can be increased when it is combined with Oxprenolol.]
[C02AA05, deserpidine, Deserpidine may increase the hypotensive activities of Oxprenolol.]
[N07AA30, ambenonium, Ambenonium may increase the bradycardic activities of Oxprenolol.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Lacosamide.]
[C03CC01, ethacrynic acid, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Oxprenolol.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Oxprenolol is combined with Levodopa.]
[S02DA01, lidocaine, The serum concentration of Lidocaine can be increased when it is combined with Oxprenolol.]
[C08EX01, lidoflazine, Oxprenolol may increase the arrhythmogenic activities of Lidoflazine.]
[C03DB01, amiloride, The risk or severity of adverse effects can be increased when Amiloride is combined with Oxprenolol.]
[N02CA07, lisuride, Oxprenolol may increase the vasoconstricting activities of Lisuride.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Lofepramine.]
[A07DA03, loperamide, Loperamide may increase the arrhythmogenic activities of Oxprenolol.]
[A12AA11, calcium pangamate, The therapeutic efficacy of Oxprenolol can be decreased when used in combination with Calcium pangamate.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Oxprenolol.]
[C10AA02, lovastatin, The metabolism of Oxprenolol can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Oxprenolol.]
[L01EG01, temsirolimus, The metabolism of Oxprenolol can be decreased when combined with Temsirolimus.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Oxprenolol can be increased when used in combination with Magnesium sulfate.]
[V04CX04, mannitol, The risk or severity of adverse effects can be increased when Mannitol is combined with Oxprenolol.]
[N06AA21, maprotiline, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Oxprenolol.]
[C02BB01, mecamylamine, Mecamylamine may increase the hypotensive activities of Oxprenolol.]
[L01AA05, mechlorethamine, Mechlorethamine may increase the bradycardic activities of Oxprenolol.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Oxprenolol.]
[M02AA18, meclofenamic acid, Meclofenamic acid may decrease the antihypertensive activities of Oxprenolol.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Medazepam.]
[C01AA08, medigoxin, Oxprenolol may increase the arrhythmogenic activities of Metildigoxin.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be decreased when Mefloquine is combined with Oxprenolol.]
[B01AB06, nadroparin, The risk or severity of hyperkalemia can be increased when Oxprenolol is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of hyperkalemia can be increased when Enoxaparin is combined with Oxprenolol.]
[B01AB04, dalteparin, The risk or severity of hyperkalemia can be increased when Oxprenolol is combined with Dalteparin.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Melatonin is combined with Oxprenolol.]
[N06DX01, memantine, Memantine may increase the bradycardic activities of Oxprenolol.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Meperidine is combined with Oxprenolol.]
[C01CA11, mephentermine, The therapeutic efficacy of Oxprenolol can be decreased when used in combination with Mephentermine.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Oxprenolol.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the hypotensive activities of Oxprenolol.]
[N01BB03, mepivacaine, The serum concentration of Mepivacaine can be increased when it is combined with Oxprenolol.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Oxprenolol.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Meptazinol.]
[N05AC03, mesoridazine, The serum concentration of Oxprenolol can be increased when it is combined with Mesoridazine.]
[N05AX13, paliperidone, Oxprenolol may increase the orthostatic hypotensive activities of Paliperidone.]
[C01CA09, metaraminol, The therapeutic efficacy of Metaraminol can be decreased when used in combination with Oxprenolol.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be increased when used in combination with Oxprenolol.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Dolasetron is combined with Oxprenolol.]
[H01CB03, lanreotide, Oxprenolol may increase the bradycardic activities of Lanreotide.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Oxprenolol.]
[N06BA03, methamphetamine, The therapeutic efficacy of Oxprenolol can be decreased when used in combination with Metamfetamine.]
[A03AB07, methantheline, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Methaqualone.]
[J05AF05, lamivudine, The serum concentration of Lamivudine can be increased when it is combined with Oxprenolol.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Oxprenolol.]
[S01EC05, methazolamide, The risk or severity of adverse effects can be increased when Methazolamide is combined with Oxprenolol.]
[G02CB05, metergoline, Oxprenolol may increase the vasoconstricting activities of Metergoline.]
[H03BB02, methimazole, The excretion of Oxprenolol can be decreased when combined with Methimazole.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Oxprenolol.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Oxprenolol.]
[N02BG08, ziconotide, Oxprenolol may increase the arrhythmogenic activities of Ziconotide.]
[N05AA02, methotrimeprazine, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA10, methoxamine, The therapeutic efficacy of Methoxamine can be decreased when used in combination with Oxprenolol.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Oxprenolol.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Oxprenolol can be increased when used in combination with Methyclothiazide.]
[C02AB01, methyldopa, The therapeutic efficacy of Methyldopa can be decreased when used in combination with Oxprenolol.]
[V04CG05, methylene blue, The serum concentration of Oxprenolol can be increased when it is combined with Methylene blue.]
[G02AB01, methylergonovine, Oxprenolol may increase the vasoconstricting activities of Methylergometrine.]
[R03DA05, aminophylline, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Aminophylline.]
[N06BA04, methylphenidate, Methylphenidate may decrease the antihypertensive activities of Oxprenolol.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Oxprenolol.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Methyprylon is combined with Oxprenolol.]
[N02CA04, methysergide, Oxprenolol may increase the vasoconstricting activities of Methysergide.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Oxprenolol.]
[C03BA08, metolazone, Metolazone may increase the hypotensive activities of Oxprenolol.]
[C07AB02, metoprolol, Metoprolol may increase the arrhythmogenic activities of Oxprenolol.]
[C01BB02, mexiletine, Mexiletine may increase the arrhythmogenic activities of Oxprenolol.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Mianserin.]
[S02AA13, miconazole, The metabolism of Oxprenolol can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, Aminophenazone may decrease the antihypertensive activities of Oxprenolol.]
[B01AB07, parnaparin, The risk or severity of hyperkalemia can be increased when Oxprenolol is combined with Parnaparin.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Midazolam is combined with Oxprenolol.]
[C01CA17, midodrine, The therapeutic efficacy of Midodrine can be decreased when used in combination with Oxprenolol.]
[G03XB01, mifepristone, The therapeutic efficacy of Mifepristone can be increased when used in combination with Oxprenolol.]
[B01AB10, tinzaparin, The risk or severity of hyperkalemia can be increased when Oxprenolol is combined with Tinzaparin.]
[C09CA03, valsartan, Valsartan may increase the hypotensive activities of Oxprenolol.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.]
[D11AX01, minoxidil, Minoxidil may increase the hypotensive activities of Oxprenolol.]
[N06BA12, lisdexamfetamine, The therapeutic efficacy of Oxprenolol can be decreased when used in combination with Lisdexamfetamine.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Molindone.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Oxprenolol.]
[C01DX12, molsidomine, Molsidomine may increase the hypotensive activities of Oxprenolol.]
[C01BD01, amiodarone, The therapeutic efficacy of Oxprenolol can be increased when used in combination with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Oxprenolol.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Oxprenolol.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Oxprenolol.]
[L04AB05, certolizumab pegol, The metabolism of Oxprenolol can be increased when combined with Certolizumab pegol.]
[G04BA01, ammonium chloride, The risk or severity of hyperkalemia can be increased when Oxprenolol is combined with Ammonium chloride.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Oxprenolol.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Vecuronium is combined with Oxprenolol.]
[N05CA02, amobarbital, Amobarbital may increase the hypotensive activities of Oxprenolol.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be decreased when Amodiaquine is combined with Oxprenolol.]
[G04CA04, silodosin, The risk or severity of orthostatic hypotension and dizziness can be increased when Oxprenolol is combined with Silodosin.]
[R03BB01, ipratropium bromide, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA17, amoxapine, The metabolism of Amoxapine can be decreased when combined with Oxprenolol.]
[N03AB05, fosphenytoin, The risk or severity of adverse effects can be increased when Fosphenytoin is combined with Oxprenolol.]
[C07AA12, nadolol, Nadolol may increase the arrhythmogenic activities of Oxprenolol.]
[N04BC04, ropinirole, Oxprenolol may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Nalbuphine is combined with Oxprenolol.]
[L04AC03, anakinra, The metabolism of Oxprenolol can be increased when combined with Anakinra.]
[S01GA01, naphazoline, The risk or severity of CNS depression can be increased when Naphazoline is combined with Oxprenolol.]
[N06BA01, amphetamine, The therapeutic efficacy of Oxprenolol can be decreased when used in combination with Amphetamine.]
[M02AA12, naproxen, Naproxen may decrease the antihypertensive activities of Oxprenolol.]
[A10BG01, troglitazone, The therapeutic efficacy of Troglitazone can be increased when used in combination with Oxprenolol.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Oxprenolol is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Oxprenolol.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Oxprenolol.]
[A10BX02, repaglinide, The therapeutic efficacy of Repaglinide can be increased when used in combination with Oxprenolol.]
[C01CX08, levosimendan, Levosimendan may increase the arrhythmogenic activities of Oxprenolol.]
[S01EB06, neostigmine, Neostigmine may increase the bradycardic activities of Oxprenolol.]
[N05AX14, iloperidone, Oxprenolol may increase the orthostatic hypotensive activities of Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Oxprenolol.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Desvenlafaxine.]
[C09CA07, telmisartan, Telmisartan may increase the hypotensive activities of Oxprenolol.]
[C10AD02, niacin, The metabolism of Oxprenolol can be decreased when combined with Niacin.]
[N06AF02, nialamide, Nialamide may increase the hypotensive activities of Oxprenolol.]
[C08CA04, nicardipine, Nicardipine may increase the arrhythmogenic activities of Oxprenolol.]
[C04AE02, nicergoline, Oxprenolol may increase the vasoconstricting activities of Nicergoline.]
[N07BA01, nicotine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Nicotine.]
[C08CA05, nifedipine, The risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Oxprenolol.]
[M02AA17, niflumic acid, Niflumic acid may decrease the antihypertensive activities of Oxprenolol.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Amyl Nitrite.]
[C08CA06, nimodipine, Nimodipine may increase the arrhythmogenic activities of Oxprenolol.]
[C08CA07, nisoldipine, Nisoldipine may increase the arrhythmogenic activities of Oxprenolol.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Nitrazepam.]
[C08CA08, nitrendipine, Nitrendipine may increase the arrhythmogenic activities of Oxprenolol.]
[R07AX01, nitric oxide, The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Oxprenolol.]
[J01XE01, nitrofurantoin, The risk or severity of hyperkalemia can be increased when Nitrofurantoin is combined with Oxprenolol.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Zaleplon is combined with Oxprenolol.]
[N04BC05, pramipexole, Oxprenolol may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, Nitroprusside may increase the hypotensive activities of Oxprenolol.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Nomifensine.]
[C01CA03, norepinephrine, Oxprenolol may decrease the bronchodilatory activities of Norepinephrine.]
[C02KX01, bosentan, Bosentan may increase the hypotensive activities of Oxprenolol.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Oxprenolol.]
[G02CA02, nylidrin, Oxprenolol may increase the arrhythmogenic activities of Nylidrin.]
[B01AB08, reviparin, The risk or severity of hyperkalemia can be increased when Oxprenolol is combined with Reviparin.]
[H01CB02, octreotide, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Oxprenolol.]
[L04AC04, rilonacept, The metabolism of Oxprenolol can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Oxprenolol can be decreased when combined with Omeprazole.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Opium.]
[R03CB03, metaproterenol, Oxprenolol may decrease the bronchodilatory activities of Orciprenaline.]
[G04CA02, tamsulosin, Oxprenolol may increase the orthostatic hypotensive activities of Tamsulosin.]
[C01AC01, ouabain, Oxprenolol may increase the bradycardic activities of Ouabain.]
[P02BA02, oxamniquine, The metabolism of Oxprenolol can be decreased when combined with Oxamniquine.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Oxazepam is combined with Oxprenolol.]
[N07XX04, sodium oxybate, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Oxycodone is combined with Oxprenolol.]
[C01DX03, oxyfedrine, The therapeutic efficacy of Oxyfedrine can be decreased when used in combination with Oxprenolol.]
[S01GA04, oxymetazoline, The risk or severity of cardiovascular complications can be increased when Oxprenolol is combined with Oxymetazoline.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Oxymorphone is combined with Oxprenolol.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Oxypertine.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may decrease the antihypertensive activities of Oxprenolol.]
[A03AB03, oxyphenonium, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[N05AH05, asenapine, Oxprenolol may increase the orthostatic hypotensive activities of Asenapine.]
[B01AB09, danaparoid, The risk or severity of hyperkalemia can be increased when Oxprenolol is combined with Danaparoid.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.]
[M03AC01, pancuronium, Pancuronium may increase the bradycardic activities of Oxprenolol.]
[G04BE02, papaverine, The risk or severity of adverse effects can be increased when Papaverine is combined with Oxprenolol.]
[N05CC05, paraldehyde, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, Pargyline may increase the hypotensive activities of Oxprenolol.]
[G04BD11, fesoterodine, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Penbutolol is combined with Oxprenolol.]
[N05AG03, penfluridol, Oxprenolol may increase the arrhythmogenic activities of Penfluridol.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Pentazocine is combined with Oxprenolol.]
[N05CA01, pentobarbital, Pentobarbital may increase the hypotensive activities of Oxprenolol.]
[C04AD03, pentoxifylline, Pentoxifylline may increase the hypotensive activities of Oxprenolol.]
[N05AB10, perazine, The serum concentration of Oxprenolol can be increased when it is combined with Perazine.]
[N04BC02, pergolide, The therapeutic efficacy of Pergolide can be decreased when used in combination with Oxprenolol.]
[C08EX02, perhexiline, Perhexiline may increase the arrhythmogenic activities of Oxprenolol.]
[N05AB03, perphenazine, The serum concentration of Oxprenolol can be increased when it is combined with Perphenazine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Oxprenolol.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Phenazocine.]
[N06AF03, phenelzine, Phenelzine may increase the hypotensive activities of Oxprenolol.]
[A10BA01, phenformin, The therapeutic efficacy of Phenformin can be increased when used in combination with Oxprenolol.]
[N03AA02, phenobarbital, Phenobarbital may increase the hypotensive activities of Oxprenolol.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Phenoperidine.]
[C04AX02, phenoxybenzamine, Oxprenolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.]
[A08AA01, phentermine, The therapeutic efficacy of Oxprenolol can be decreased when used in combination with Phentermine.]
[V03AB36, phentolamine, Oxprenolol may increase the orthostatic hypotensive activities of Phentolamine.]
[M02AA01, phenylbutazone, Phenylbutazone may decrease the antihypertensive activities of Oxprenolol.]
[S01GA05, phenylephrine, The therapeutic efficacy of Phenylephrine can be decreased when used in combination with Oxprenolol.]
[R01BA01, phenylpropanolamine, Oxprenolol may decrease the bronchodilatory activities of Phenylpropanolamine.]
[N03AB02, phenytoin, The risk or severity of adverse effects can be increased when Phenytoin is combined with Oxprenolol.]
[L04AB06, golimumab, The metabolism of Oxprenolol can be increased when combined with Golimumab.]
[V03AB19, physostigmine, Physostigmine may increase the bradycardic activities of Oxprenolol.]
[C08CX01, mibefradil, Mibefradil may increase the arrhythmogenic activities of Oxprenolol.]
[S01EB01, pilocarpine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Pilocarpine.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Oxprenolol.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Pindolol is combined with Oxprenolol.]
[J05AE01, saquinavir, The metabolism of Oxprenolol can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Piperazine can be decreased when combined with Oxprenolol.]
[N05AC04, pipothiazine, The serum concentration of Oxprenolol can be increased when it is combined with Pipotiazine.]
[C09CA02, eprosartan, Eprosartan may increase the hypotensive activities of Oxprenolol.]
[A02BX03, pirenzepine, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Piritramide.]
[S01BC06, piroxicam, Piroxicam may decrease the antihypertensive activities of Oxprenolol.]
[N02CX01, pizotyline, Oxprenolol may increase the orthostatic hypotensive activities of Pizotifen.]
[J05AG02, delavirdine, The metabolism of Oxprenolol can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, Irbesartan may increase the hypotensive activities of Oxprenolol.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Proxibarbal.]
[A10BG02, rosiglitazone, The therapeutic efficacy of Rosiglitazone can be increased when used in combination with Oxprenolol.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Alosetron is combined with Oxprenolol.]
[L04AC08, canakinumab, The metabolism of Oxprenolol can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The therapeutic efficacy of Oxprenolol can be increased when used in combination with Polythiazide.]
[J05AE03, ritonavir, The metabolism of Oxprenolol can be decreased when combined with Ritonavir.]
[A10BH03, saxagliptin, The therapeutic efficacy of Saxagliptin can be increased when used in combination with Oxprenolol.]
[B05XA01, potassium chloride, Potassium chloride may increase the hyperkalemic activities of Oxprenolol.]
[V03AB21, potassium iodide, Potassium Iodide may increase the hyperkalemic activities of Oxprenolol.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be increased when used in combination with Oxprenolol.]
[C07AB01, practolol, Practolol may increase the arrhythmogenic activities of Oxprenolol.]
[C01BA08, prajmaline, Oxprenolol may increase the arrhythmogenic activities of Prajmaline.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Prazepam.]
[C02CA01, prazosin, The risk or severity of hypotension can be increased when Prazosin is combined with Oxprenolol.]
[C01DX02, prenylamine, Oxprenolol may increase the arrhythmogenic activities of Prenylamine.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Prilocaine is combined with Oxprenolol.]
[P01BA03, primaquine, The metabolism of Oxprenolol can be decreased when combined with Primaquine.]
[N03AA03, primidone, Primidone may increase the hypotensive activities of Oxprenolol.]
[C01BA02, procainamide, Procainamide may increase the arrhythmogenic activities of Oxprenolol.]
[S01HA05, procaine, Procaine may increase the bradycardic activities of Oxprenolol.]
[L01XB01, procarbazine, Procarbazine may increase the hypotensive activities of Oxprenolol.]
[N05AB04, prochlorperazine, The serum concentration of Oxprenolol can be increased when it is combined with Prochlorperazine.]
[N04AA04, procyclidine, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The metabolism of Progesterone can be decreased when combined with Oxprenolol.]
[N05AA03, promazine, The serum concentration of Oxprenolol can be increased when it is combined with Promazine.]
[R06AD02, promethazine, The serum concentration of Oxprenolol can be increased when it is combined with Promethazine.]
[C01BC03, propafenone, The risk or severity of adverse effects can be increased when Propafenone is combined with Oxprenolol.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Propanidid.]
[A03AB05, propantheline, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The serum concentration of Oxprenolol can be increased when it is combined with Periciazine.]
[N05CM06, propiomazine, Oxprenolol may increase the orthostatic hypotensive activities of Propiomazine.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Oxprenolol.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Oxprenolol.]
[C07AA05, propranolol, Propranolol may increase the arrhythmogenic activities of Oxprenolol.]
[C01AB01, proscillaridin, Oxprenolol may increase the bradycardic activities of Proscillaridin.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Rizatriptan is combined with Oxprenolol.]
[B01AC09, epoprostenol, Epoprostenol may increase the hypotensive activities of Oxprenolol.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Protriptyline is combined with Oxprenolol.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Oxprenolol can be decreased when used in combination with Pseudoephedrine.]
[N05AX12, aripiprazole, The risk or severity of hypotension can be increased when Aripiprazole is combined with Oxprenolol.]
[N07XX07, dalfampridine, The serum concentration of Dalfampridine can be increased when it is combined with Oxprenolol.]
[A03AB15, diphemanil, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Oxprenolol.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Pyrantel.]
[A12BA05, potassium gluconate, Potassium gluconate may increase the hyperkalemic activities of Oxprenolol.]
[N07AA02, pyridostigmine, Pyridostigmine may increase the bradycardic activities of Oxprenolol.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Mepyramine.]
[C01BA01, quinidine, Quinidine may increase the arrhythmogenic activities of Oxprenolol.]
[P01BC01, quinine, The metabolism of Oxprenolol can be decreased when combined with Quinine.]
[A02BA02, ranitidine, The serum concentration of Ranitidine can be increased when it is combined with Oxprenolol.]
[C02AA01, rescinnamine, Rescinnamine may decrease the antihypertensive activities of Oxprenolol.]
[C02AA02, reserpine, Reserpine may increase the hypotensive activities of Oxprenolol.]
[J04AB02, rifampin, The metabolism of Oxprenolol can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, The therapeutic efficacy of Rimiterol can be decreased when used in combination with Oxprenolol.]
[G02CA01, ritodrine, Oxprenolol may decrease the bronchodilatory activities of Ritodrine.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Oxitriptan.]
[N02BA05, salicylamide, Salicylamide may decrease the antihypertensive activities of Oxprenolol.]
[A07EC01, sulfasalazine, Sulfasalazine may decrease the antihypertensive activities of Oxprenolol.]
[S01BC08, salicylic acid, Salicylic acid may decrease the antihypertensive activities of Oxprenolol.]
[S01FA02, scopolamine, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, Secobarbital may increase the hypotensive activities of Oxprenolol.]
[N04BD01, selegiline, Selegiline may increase the hypotensive activities of Oxprenolol.]
[L01FA03, obinutuzumab, Oxprenolol may increase the hypotensive activities of Obinutuzumab.]
[C07AA07, sotalol, Sotalol may increase the arrhythmogenic activities of Oxprenolol.]
[C03DA01, spironolactone, The risk or severity of adverse effects can be increased when Spironolactone is combined with Oxprenolol.]
